{"id":25709,"date":"2022-12-23T23:34:48","date_gmt":"2022-12-23T23:34:48","guid":{"rendered":"https:\/\/mailinvest.blog\/index.php\/2022\/12\/23\/streamlining-the-kubernetes-workload-to-speed-new-drug-discovery\/"},"modified":"2022-12-23T23:34:48","modified_gmt":"2022-12-23T23:34:48","slug":"streamlining-the-kubernetes-workload-to-speed-new-drug-discovery","status":"publish","type":"post","link":"https:\/\/mailinvest.blog\/index.php\/2022\/12\/23\/streamlining-the-kubernetes-workload-to-speed-new-drug-discovery\/","title":{"rendered":"Streamlining the Kubernetes workload to speed new drug discovery"},"content":{"rendered":"

<\/a>\n
<\/p>\n

\n

Kubernetes has revolutionized cloud computing, but it can also chew up a lot of time<\/a> for developers.<\/p>\n

The process often involves building a container image, deploying an EC2 instance, allocating memory, placing the app in a virtual machine, and running the instance against the app. Then it comes time to pay for it all.<\/p>\n

This can be a laborious exercise, and it is one reason why platforms, such as the managed Kubernetes service offered by Rafay Systems Inc.<\/a>, are gaining traction by abstracting away infrastructure headaches from developers in the enterprise world.<\/p>\n

\u201cIn a CIO survey, 80% of the time of developers is wasted on infrastructure stuff and not on innovation,\u201d said Haseeb Budhani<\/a> (pictured, left), co-founder and chief executive officer at Rafay. \u201cWe need to bring that 80% back so that 100% of the work is on innovation and today it\u2019s not. That\u2019s what we do.\u201d<\/p>\n

Budhani spoke with theCUBE hosts\u00a0Lisa Martin<\/a> and Dave Vellante<\/a> at AWS re:Invent<\/a>, during an exclusive broadcast on theCUBE, SiliconANGLE Media\u2019s livestreaming studio. He was joined by Rakesh Singh<\/a> (pictured, right), head of cloud & DevOps at Regeneron Pharmaceuticals Inc., and they discussed how Rafay\u2019s managed Kubernetes solution helped Regeneron speed drug discovery. (* Disclosure below.)<\/em><\/p>\n

Focus on business activity<\/h3>\n

For a major player in the drug development industry such as Regeneron, speed-to-market is of paramount importance. The company became a Rafay customer in the hope that developers would be empowered to increase the pace of innovation which has led to the production of medicines for eye disease, cancer, and cardiovascular ailments.<\/p>\n

\u201cWe need to make sure we are leveraging platforms and tools to enable our developers to focus on key business activity rather than doing redundant things,\u201d Singh said. \u201cWe were able to discover new drugs and get them to the market at a much faster pace. That whole process was expedited using these tools and processes.\u201d<\/p>\n

The founders at Rafay were motivated to address the need to abstract away Kubernetes operations for developers after enduring countless hours spent managing the container platform at a previous company.<\/p>\n

\u201cDevelopers should write their code, check it, and never have to think about it again,\u201d Budhani said. \u201cWhat is Kubernetes? I don\u2019t care. That\u2019s the right answer.\u201d<\/p>\n

Here\u2019s the complete video interview, part of SiliconANGLE\u2019s and theCUBE\u2019s coverage of AWS re:Invent<\/a>:<\/p>\n